Heparin as an anticancer therapeutic

Expert Opinion on Investigational Drugs

Volumn 17, Issue 7, 2008, Pages 1029-1037

  Zacharski, Leo R ^a   Lee, Agnes Y Y ^b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Angiogenesis; Anticoagulant; Cancer survival; Heparin; Low molecular weight heparin; Neoplasm; Oxidative stress; Thromboembolism

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; COUMARIN; CYCLOPHOSPHAMIDE; DALTEPARIN; EPIRUBICIN; FONDAPARINUX; GEMCITABINE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARANASE; HEPARIN; IRON; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PARA COUMARIC ACID; PI 88; PLACEBO; VINCRISTINE; WARFARIN;

ADJUVANT THERAPY; ADVANCED CANCER; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG SCREENING; DRUG STRUCTURE; FIBRINOLYSIS; HUMAN; HYPERCOAGULABILITY; IRON METABOLISM; LOW DRUG DOSE; LUNG EMBOLISM; LUNG SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; METASTASIS INHIBITION; METASTASIS POTENTIAL; MONOTHERAPY; NONHUMAN; OXIDATIVE STRESS; PANCREAS CANCER; REVIEW; RISK REDUCTION; SOLID TUMOR; THROMBOEMBOLISM; THROMBOSIS; UTERINE CERVIX CANCER; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HEPARIN; HUMANS; NEOPLASMS; OXIDATION-REDUCTION;

EID: 48249090375     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.7.1029     Document Type: Review

References (84)

1. Zacharski LR, Ornstein DL. Heparin and cancer. Thromb Haemost 1998;80:10-23
2. Vlodavsky I, Abboud-Jarrous G, Elkin M, et al. The impact of heparanese and heparin on cancer metastasis and angiogenesis. Pathophysiol Haemost Thromb 2006;35:116-27
3. Vlodavsky I, Ilan N, Nadir Y, et al. Heparanase, heparin and the coagulation system in cancer progression. Thromb Res 2007;120(Suppl 2):S112-20
4. Vreys V, David G. Mammalian heparanase: what is the message? J Cell Mol Med 2007;11:427-52
5. Amirkhosravi A, Meyer T, Amaya M, et al. The role of tissue factor pathway inhibitor in tumor growth and metastasis. Semin Thromb Hemost 2007;33:643-52
6. Shworak NW. Heparan sulfate proteoglycans. In: Aird WC, editor, Endothelial biomedicine. Cambridge: Cambridge University Press; 2007. p. 947-59
7. Iozzo MV. Proteoglycans: structure, biology and molecular interactions. New York: Marcel Dekker, Inc.; 2000. p. 27-59
8. Linhardt RJ, Dordick JS, Deangelis PL, Liu J. Enzymatic synthesis of glycosaminoglycan heparin. Semin Thromb Hemost 2007;33:453-65
9. Proteoglycans and glycosaminoglycans, maintained by Bob Lauder. Available from: http://biol.lancs.ac.uk/gig/pages/toppage. htm [Last accessed 25 January 2008]
10. Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007;446:1030-7
11. Esko JD, Selleck SB. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Ann Rev Biochem 2002;71:435-71
12. Esko JD, Lindahl U. Molecular diversity of heparan sulfate. J Clin Invest 2001;108:169-73
13. Fico A, Maina F, Dono R. Fine-tuning of cell signalling by glypicans. Cell Mol Life Sci 2007 [Epub ahead of print]
14. Mousa SA. Low-molecular-weight heparins in thrombosis and cancer: emerging links. Cardiovasc Drug Rev 2004;22:121-34
15. Mousa SA. Heparin, low molecular weight heparin, and derivatives in thrombosis, angiogenesis, and inflammation: emerging links. Semin Thromb Hemost 2007;33:524-33
16. Guerrini M, Guglieri S, Naggi A, et al. Low molecular weight heparins: structural differentiation by bidimensional nuclear magnetic resonance spectroscopy. Semin Thromb Hemost 2007;33:478-87
17. Gallagher JT. Heparan sulfate: growth control with a restricted sequence menu. J Clin Invest 2001;108:357-61
18. Backen AC, Cole CL, Lau SC, et al. Heparan sulphate synthetic and editing enzymes in ovarian cancer. Br J Cancer 2007;96:1544-8
19. Chen JL, Hong J, Lu JL, et al. Effect of non-anticoagulant N-desulfated heparin on expression of vascular endothelial growth factor, angiogenesis and metastasis of orthotopic implantation of human gastric carcinoma. World J Gastroenterol 2007;13:457-61
20. Bar-Ner M, Eldor A, Wasserman L, et al. Inhibition of heparanase-mediated degradation of extra cellular matrix heparan sulfate by non-anticoagulant heparin species. Blood 1987;70:551-7
21. Hostettler N, Naggi A, Torri G, et al. P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. FASEB J 2007;21:3562-72
22. Borsig L. Non-anticoagulant effects of heparin in carcinoma metastasis and Troussea's syndrome. Pathophysiol Haemost Thromb 2003;33(Suppl 1):64-6
23. Mousa SA, Linhardt R, Francis JL, Amirkhosravi A. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb Haemost 2006;96:816-21
24. Ono K, Ishihara M, Ishikawa K, et al. Periodate-treated, non-anticoagulant heparin-carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumour growth and metastasis to the lung. Br J Cancer 2002;86:1803-12
25. Stevenson JL, Varki A, Borsig L. Heparin attenuates metastasis mainly due to inhibition of P- and L-selectin, but non-anticoagulant heparins can have additional effects. Thromb Res 2007;120(Suppl 2):S107-11
26. Yoshitomi Y, Nakanishi H, Kusano Y, et al. Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity. Cancer Lett 2004;207:165-74
27. Gao Y, Li N, Fei R, et al. P-Selectin-mediated acute inflammation can be blocked by chemically modified heparin, RO-heparin. Mol Cells 2005;19:350-5
28. Kouretas PC, Hannan RL, Kapur NK, et al. Non-anticoagulant heparin increases endothelial nitric oxide synthase activity: role of inhibitory guanine nucleotide proteins. J Mol Cell Cardiol 1998;30:2669-82
29. Ferro V, Dredge K, Liu L, et al. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin Thromb Hemost 2007;33:557-68
30. Fairweather JK, Hammond E, Johnstone KD, Ferro V. Synthesis and heparanase inhibitory activity of sulfated mannooligosaccharides related to the antiangiogenic agent PI-88. Bioorg Med Chem 2008;16(2):699-709
31. Weitz JI, Linkins LA. Beyond heparin and warfarin: the new generation of anticoagulants. Expert Opin Investig Drugs 2007;16:271-82
32. Karoli T, Liu L, Fairweather JK, et al. Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88). J Med Chem 2005;48:8229-36
33. Ludwig RJ, Alban S, Bistrian R, et al. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb Haemost 2006;95:535-40
34. Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins-correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res 2005;11(19 Pt 1):7003-11
35. Khorana AA, Sahni A, Altland OD, Francis CW. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol 2003;23:2110-5
36. Akl EA, van Doormaal FF, Barba M, et al. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst Rev 2007:CD006652
37. Zacharski LR. Anticoagulants in cancer treatment: Malignancy as a solid phase coagulopathy. Cancer Lett 2002;186:1-9
38. Zacharski LR. Malignanancy as a solid phase coagulopathy: implications for the etiology, pathogenesis and treatment of cancer. Semin Thromb Hemost 2003;29:239-46
39. Icli F, Akbulut H, Utkan G, et al. Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J Surg Oncol 2007;95:507-12
40. von Delius S, Ayvaz M, Wagenpfeil S, et al. Effect of low-molecular-weight heparin on survival in patients with advanced pancreatic adenocarcinoma. Thromb Haemost 2007;98:434-9
41. Nakchbandi W, Müller H, Singer MV, et al. Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma. Scand J Gastroenterol 2006;41:1095-104
42. Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343:886-9
43. von Tempelhoff GF, Harenberg J, Niemann F, et al. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol 2000;16:815-24
44. Haas SK, Kakkar AK, Kemkes-Matthes B, et al. Prevention of VTE with LMWH in patients with metastatic breast or lung cancer-results of the TOPIC studies [abstract OR059]. J Thromb Haemost 2005;3(Suppl 1).
45. Henry BL, Monien BH, Bock PE, Desai UR. A novel allosteric pathway of thrombin inhibition: exosite II mediated potent inhibition of thrombin by chemo-enzymatic, sulfated dehydropolymers of 4-hydroxycinnamic acids. J Biol Chem 2007;282:31891-9
46. Lv H, Yu G, Sun L, et al. Elevated level of glycosaminoglycans and altered sulfation pattern of chondroitin sulfate are associated with differentiation status and histological type of human primary hepatic carcinoma. Oncology 2008;72:347-56
47. Theocharis AD, Tsara ME, Papageorgacopoulou N, et al. Pancreatic carcinoma is characterized by elevated content of hyaluronan and chondroitin sulfate with altered disaccharide composition. Biochim Biophys Acta 2000;1502:201-6
48. Tsara ME, Papageorgacopoulou N, Karavias DD, Theocharis DA. Distribution and changes of glycosaminoglycans in neoplasias of rectum. Anticancer Res 1995;15:2107-12
49. Kennett EC, Davies MJ. Degradation of matrix glycosaminoglycans by peroxynitrite/peroxynitrous acid: evidence for a hydroxyl-radical-like mechanism. Free Radic Biol Med 2007;42:1278-89
50. Kramer A, van den Hoven M, Rops A, et al. Induction of glomerular heparanase expression in rats with adriamycin nephropathy is regulated by reactive oxygen species and the renin-angiotensin system. J Am Soc Nephrol 2006;17:2513-20
51. Ames BN. Enclogenous oxidative DNA damage, aging, and cancer. Free Radic Res Commun 1989;7:128-38
52. Cerutti PA. Oxy-radicals and cancer. Lancet 1994;344:862-3
53. Grant D, Long WF, Mackintosh G, Williamson FB. The antioxidant activity of heparins. Biochem Soc Trans 1996;24:194S
54. Vismara E, Pierini M, Guglieri S, et al. Structural modification induced in heparin by a Fenton-type depolymerization process. Semin Thromb Hemost 2007;33:466-77
55. Metcalfe DD, Thompson HL, Klebanoff SJ, Henderson WR Jr. Oxidative degradation of rat mast-cell heparin proteoglycan. Biochem J 1990;272:51-7
56. Zielonka J, Rybak M, Celi ska J, et al. Effect of heparin on viologen-stimulated enzymatic NADH depletion. Chem Res Toxicol 2006;19:668-73
57. Baldus S, Rudolph V, Roiss M, et al. Hepatitis increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation 2006;113:1871-8
58. Ross MA, Long WF, Williamson FB. Inhibition by heparin of Fe(II)-catalysed free-radical peroxidation of linolenic acid. Biochem J 1992;286:717-20
59. Ross MA, Long WF, Williamson FB. Heparin reduces Fe(II)-catalyzed peroxidation of linolenic acid. Biochem Soc Trans 1992;20:6S
60. Albertini R, Rindi S, Passi A, et al. The effect of heparin on Cu(2+)-mediated oxidation of human low-density lipoproteins. FEBS Lett 1995;377:240-2
61. Albertind R, Rindi S, Passi A, et al. Heparin protection against Fe2+ and Cu2+ -mediated oxidation of liposomes. FEBS Lett 1996;383:155-8
62. Rajeswar, A, Varalakshmi P. Low molecular weight heparin protection against oxalate-induced oxidative renal insult. Clin Chim Acta. 2006;370:108-14
63. Manduteanu I, Dragomir E, Voinea M, et al. Enoxaparin reduces H2O2-induced activation of human endothelial cells by a mechanism involving cell adhesion molecules and nuclear transcription factors. Pharmacology 2007;79:154-62
64. Poyrazoglu OK, Dogukan A, Yalniz M, et al. Acute effect of standard heparin versus low molecular weight heparin on oxidative stress and inflammation in hemodialysis patients. Ren Fail 2006;28:723-7
65. Aoyagi K, Kuzure Y, Shahrzad S, et al. Inhibition by heparin of protein kinase C activation and hydroxyl radical generation in puromycin aminonucleoside treated isolated rat hepatocytes. Mol Cell Biochem 2003;244:3-9
66. Levenson CW, Tassabehji NM. Iron and ageing: an introduction to iron regulatory mechanisms. Ageing Res Rev 2004;3:251-63
67. Papanikolaou G, Pantopoulos K. Iron metabolism and toxicity. Toxicol Appl Pharmacol 2005;202:199-211
68. Kehrer JP. The Haber-Weiss reaction and mechanisms of toxicity. Toxicology 2000;149:43-50
69. Spiteller G. Lipid peroxidation in aging and age-dependent diseases. Exp Gerontol 2001;36:1425-57
70. Cook CI, Yu BP. Iron accumulation in aging: modulation by dietary restriction. Mech Ageing Dev 1998;102:1-13
71. Zacharski LR, Chow BK, Howes PS, et al. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease. JAMA 2007;297:603-10
72. Zacharski LP, Chow BK. Iron reduction and cardiovascular outcomes [Letter-to-editor]. JAMA 2007;297:2075-6
73. Zacharski LR, Chow BK, Howes PS, et al. Reducing iron stores lowers cancer risk in patients with peripheral arterial disease [abstract 2665]. ASH Annual Meeting Abstracts; 2007;110(11)
74. Lapenna D, Mezzetti A, de Gioia S, et al. Heparin: does it act as an antioxidant in vivo? Biochem Pharmacol 1992;44:188-91
75. Dolovich LR, Ginsberg JS, Douketis JD, et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000;160(2):181-8
76. Green D, Hull RD, Brant R, Pineo GF. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin [letter]. Lancet 1992;339(8807):1476
77. Hettiarachchi RJ, Smorenburg SM, Ginsberg J, et al. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 1999;82(2):947-52
78. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin therapy with dalteparin and survival in advanced cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 2004;22(10):1944-8
79. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23(10):2130-5
80. Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004;2(8):1266-71
81. Sideras K, Schaefer PL, Okuno SH, et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc 2006;81(6):758-67
82. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23(10):2123-9
83. Kuderer NM, Khorana AA, Lyman GH, Francis CW. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 2007;110(5):1149-61
84. Lazo-Langner A, Goss GD, Spaans JN, Rodger MA. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 2007;5(4):729-37